Haematological Problems in Pregnancy

Dewhurst's Textbook of Obstetrics & Gynaecology: Eighth Edition

Volumn , Issue , 2012, Pages 151-172

  Clark, Peter ^a   Thomson, Andrew J ^b   Greer, Ian A ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anaemia; Haemophilia; HDN; Sickle cell; Thalassaemia; Thrombocytopenia; Venous thrombosis; Von willebrand's disease

Indexed keywords

EID: 84885542988     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119979449.ch15     Document Type: Chapter

References (112)

1. Pena-Rosas J, Viteri F. Effects and safety of preventive oral iron or iron + folic acid supplementation for women during pregnancy. Cochrane Database Syst Rev 2009;(4): CD004736.
2. Ali S, Economides D. Folic acid supplementation. Curr Opin Obstet Gynecol 2000; 12: 507-512.
3. Hibbard E, Smithells R. Folic acid metabolism and human embryopathy. Lancet 1965; i: 1254-1256.
4. Ray J, Blom H. Vitamin B12 insufficiency and the risk of fetal neural tube defects. Q J Med 2003; 96: 289-295.
5. Hindmarsh PC, Geary MP, Rodeck CH, Jackson MR, Kingdom JC. Effects of early maternal iron stores on placental weight and structure. Lancet 2000; 356: 719-723.
6. Pardo J, Peled Y, Bar J et al. Evaluation of low serum vitamin B(12) in the non-anaemic pregnant patient. Hum Reprod 2000; 15: 224-226.
7. van den Broek NR, Letsky EA, White SA, Shenkin A. Iron status in pregnant women: which measurements are valid. Br J Haematol 1998; 103: 817-824.
8. Andersson A, Hultberg B, Brattström L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992; 30: 377-379.
9. Qvist I, Abdulla M, Jägerstad M, Svensson S. Iron, zinc and folate status during pregnancy and two months after delivery. Acta Obstet Gynecol Scand 1986; 65: 15-22.
10. Commentary. Does folic acid harm people with vitamin B12 deficiency. Q J Med 1995; 88: 357-364.
11. Old J. Screening and genetic diagnosis of haemoglobinopathies. Scand J Clin Lab Invest 2007; 67: 71-86.
12. Chui D, Waye J. Hydrops fetalis caused by alpha-thalassaemia: an emerging health care problem. Blood 1998; 91: 2213-2222.
13. Aessopos A, Karabatsos F, Farmakis D et al. Pregnancy in patients with well-treated beta-thalassaemia: outcome for mothers and newborn infants. Am J Obstet Gynecol 1999; 180: 360-365.
14. Jensen C, Tuck S, Wonke B. Fertility in beta-thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet Gynaecol 1995; 102: 625-629.
15. Mordel N, Birkenfeld A, Goldfarb AN, Rachmilewitz EA. Successful full-term pregnancy in homozygous beta-thalassaemia major: case report and review of the literature. Obstet Gynecol 1989; 73: 837-839.
16. Nassar AH, Usta IM, Rechdan JB, Koussa S, Inati A, Taher AT. Pregnancy in patients with beta thalassemia intermedia: outcomes of mothers and newborns. Am J Hematol 2006; 81: 499-502.
17. Sheiner E, Levy A, Yerushalmi R, Katz M. Beta-thalassaemia minor during pregnancy. Obstet Gynecol 2004; 103: 1273-1277.
18. Ryan K, Bain BJ, Worthington D et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010; 149: 35-49.
19. American College of Obstetricians and Gynecologists. Haemoglobinopathies in pregnanc. ACOG Practice Bulletin No. 78. Obstet Gynecol 2007; 109: 229-237.
20. Leung WC, Leung KY, Lau ET, Tang MH, Chan V. Alpha-thalassaemia. Semin Fetal Neonatal Med 2008; 13: 215-222.
21. Hahn S, Zhong X, Holzgreve W. Recent progress in non-invasive prenatal diagnosis. Semin Fetal Neonatal Med 2008; 13: 57-62.
22. Rahimy MC, Gangbo A, Adjou R, Deguenon C, Goussanou S, Alihonou E. Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting. Blood 2000; 96: 1685-1689.
23. Koshy M. Sickle cell disease and pregnancy. Blood Rev 1995; 9: 157-164.
24. Rees DC, Olujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003; 120: 744-752.
25. Martí-Carvajal AJ, Peña-Martí GE, Comunián-Carrasco G, Martí-Peña AJ. Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database Syst Rev 2009;(1): CD006786.
26. Mahomed K. Prophylactic versus selective blood transfusion for sickle cell anaemia during pregnancy. Cochrane Database Syst Rev 2006;(3): CD000040.
27. Urbaniak S, Greiss M. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000; 14: 44-61.
28. Roberts IA. The changing face of haemolytic disease of the newborn. E arly Hum Dev 2008; 84: 515-523.
29. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for blood grouping and red cell antibody testing during pregnancy. Transfus Med 1996; 6: 71-74.
30. Working Party of the British Committee for Standards in Haematology, Transfusion Taskforce. Guidelines for the Estimation of Fetomaternal Haemorrhage. London: British Society for Haematology, 2009. Available at: www.bcshguidelines.com/ documents/BCSH_FMH_bcsh_sept2009.pdf
31. British Committee for Standards in Haematology. Guidelines for the Use of Prophylactic Anti-D Immunoglobulin. London: British Society for Haematology, 2006. Available at: www. bcshguidelines.com/documents/Anti-D_bcsh_07062006.pdf
32. Lo Y, Bowell PJ, Selinger M et al. Prenatal determination of fetal rhesus D status by DNA amplification of peripheral blood of rhesus-negative mothers. Ann NY Acad Sci 1994; 731: 229-236.
33. van der Schoot C, Hahn S, Chitty LS. Non-invasive prenatal diagnosis and determination of fetal Rh status. Semin Fetal Neonatal Med 2008; 13: 63-68.
34. Moise KJ Jr. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol 2008; 198: 161.e1-4.
35. National Institute for Health and Clinical Excellence. Pregnancy (Rhesus-negative Women): Routine Anti-D. Technology appraisal TA156. London: NICE, 2008. Available at: http://guidance. nice.org.uk/TA156
36. Royal College of Obstetricians and Gynaecologists. The Use of Anti-D Immunoglobulin for Rhesus D Prophylaxis. Green-top Guideline No. 22, 2011. Available at: www.rcog.org.uk/files/ rcog-corp/GTG22AntiD.pdf
37. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43: 1661-1666.
38. MacKenzie IZ, Bowell P, Gregory H, Pratt G, Guest C, Entwistle CC. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol 1999; 106: 492-497.
39. Daniels G, Poole J, de Silva M, Callaghan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. Transfus Med 2002; 12: 287-295.
40. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596.
41. Arnold D, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
42. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008; 2008: 271363.
43. Franchini M, Zaffanello M, Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Res 2006; 118: 177-184.
44. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Curr Opin Hematol 2003; 10: 339-344.
45. Esplin M, Branch D. Diagnosis and management of thrombotic microangiopathies during pregnancy. Clin Obstet Gynecol 1999; 42: 360-367.
46. Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 2005; 3: 2420-2427.
47. Stella CL, Dacus J, Guzman E et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol 2009; 200: 381-384.
48. Martin JN Jr, Bailey AP, Rehberg JF, Owens MT, Keiser SD, May WL. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol 2008; 199: 98-104.
49. Gerth J, Schleussner E, Kentouche K, Busch M, Seifert M, Wolf G. Pregnancy-associated thrombotic thrombocytopenic purpura. T hromb Haemost 2009; 101: 248-251.
50. Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17: 459-463.
51. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2009; 148: 37-47.
52. Scully MA, Machin SJ. Berend Houwen Memorial Lecture: ISLH Las Vegas May 2009: the pathogenesis and management of thrombotic microangiopathies. Int J Lab Hematol 2009; 31: 268-276.
53. Blanco-Molina A, Trujillo-Santos J, Criado J et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190.
54. Centre for Maternal and Child Enquiries. Saving Mothers ' Lives: Reviewing Maternal Deaths to Make Motherhood Safer, 2003-2005. The Seventh Report of the Confiential Enquiries into Maternal Deaths in the United Kingdom. London: CMACE, 2007. Available at: www.cmace.org.uk/getattachment/26dae364-1fc9-4a29-a6cb-afb3f251f8f7/Saving-Mothers '-Lives-2003-2005-(Full-report).aspx
55. Confidential Enquiry into Maternal and Child Health. Stillbirth, Neonatal and Post-neonatal Mortality 2000-2003. England, Wales and Northern Ireland. London: CEMACH, 2005. Available at: www.cmace.org.uk/getattachment/f0dc4ef6- 71e9- 4ec2- 8221- f118522b5f3c/Stillbirth,-Neonatal-and-Perinatal-Mortality-2000-.aspx
56. Ray J, Chan W. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54: 265-271.
57. Chan W, Spencer F, Ginsberg J. Anatomical distribution of deep vein thrombosis in pregnancy. Can Med Assoc J 2010; 182: 641.
58. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170.
59. Greer I, Thomson A. Management of venous thromboembolism in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15: 583-603.
60. McColl M, Ramsay J, Tait R. Risk factors for pregnancy-associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-1188.
61. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 163: 627S-644S.
62. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010; 340: c2541.
63. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-257.
64. Royal College of Obstetricians and Gynaecologists. The Investigation and Treatment of Women with Recurrent Miscarria. Green-top Guideline No. 17, 2003. Available at: www.rcog. org.uk/files/rcog-corp/uploaded-files/GT17RecurrentMiscarriage2003.pdf
65. Kujovich J. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004; 191: 412-424.
66. Rodger M, Paidas M, McLintock C et al. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008; 112: 320-324.
67. Rodger M, Betancourt MT, Clark P et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7: e1000292.
68. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 844S-886S.
69. Walker M, Ferguson S, Allen V. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database Syst Rev 2003;(2): CD003580.
70. Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000; 107: 415-419.
71. De Stefano V, Martinelli I, Rossi E et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135: 386-391.
72. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Thrombosis and Embolism During Pregnancy and the Puerperium. Green-top Guideline No. 37a, 2009. Available at: www.rcog.org.uk/files/rcog-corp/GTG37aReducingRisk Thrombosis.pdf
73. Royal College of Obstetricians and Gynaecologists. The Acute Management of Thrombosis and Embolism During Pregnancy and the Puerperium. Green-top Guideline No. 37b, 2007. Available at: www.rcog.org.uk/files/rcog-corp/GTG37b1022011.pdf
74. Francalanci I, Comeglio P, Alessandrello Liotta A et al. D-dimer plasma levels during normal pregnancy measured by specific ELISA. Int J Clin Lab Res 1997; 27: 65-67.
75. Kovac M, Mikovic Z, Rakicevic L et al. The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol 2010; 148: 27-30.
76. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58: 470-484.
77. Ridge CA, McDermott S, Freyne BJ, Brennan DJ, Collins CD, Skehan SJ. Pulmonary embolism in pregnancy: comparison of pulmonary CT angiography and lung scintigraphy. AJR Am J Roentgenol 2009; 193: 1223-1227.
78. Cook J, Kyriou J. Radiation from CT and perfusion scanning in pregnancy. BMJ 2005; 331: 350.
79. Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: case series. BJOG 2002; 109: 1020-1024.
80. Chan W, Anand S, Ginsberg J. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-196.
81. Schaefer C, Hannemann D, Meister R et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95: 949-957.
82. Greer I, Nelson-Piercy C. Low-molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.
83. Magnani H. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid. Thromb Res 2010; 125: 297-302.
84. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 340S-380S.
85. Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia 2009; 15: 990-1005.
86. Mannucci P. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1998; 72: 1449-1455.
87. Kujovich J. von Willebrand disease and pregnancy. J Thromb Haemost 2005; 3: 246-253.
88. Chi C, Hyett JA, Finning KM, Lee CA, Kadir RA. Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia. BJOG 2006; 113: 239-242.
89. Lee CA, Chi C, Pavord SR et al. The obstetric and gynaecological management of women with inherited bleeding disorders: review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors ' Organization. Haemophilia 2006; 12: 301-306.
90. Madan B, Street A. What is the optimal mode of delivery for the haemophilia carrier expecting an affected infant: vaginal delivery or caesarean delivery? Haemophilia 2010; 16: 425-426.
91. Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand 2009; 88: 1095-1100.
92. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand ' s disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314-321.
93. Clark P. Changes in haemostasis variables in pregnancy. Semin Vasc Med 2003; 3: 13-24.
94. Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 37-41.
95. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-749.
96. Collins PW, Goldman E, Lilley K, Pasi KJ, Lee CA. Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia 1995; 1: 227-231.
97. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand ' s disease. Blood 1997; 69: 454-459.
98. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-898.
99. Nichols W, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
100. Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand ' s disease and different von Willebrand factor mutations. Haematologica 2010; 95: 963-969.
101. Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 282-285.
102. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 909-918.
103. Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand ' s disease. Blood 1987; 69: 786-789.
104. Pasi K, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors ' Organization. Haemophilia 2004; 10: 218-231.
105. Kouides P. Current understanding of von Willebrand ' s disease in women: some answers, more questions. Haemophilia 2006; 12 (Suppl 3): 43-51.
106. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-599.
107. Jacobsen A, Skjeldestad F, Sandset P. Ante-and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6: 905-912.
108. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194: 1311-1315.
109. Knight M. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG 2008; 115: 453-461.
110. Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
111. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiological procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989; 61: 189-196.
112. Winer-Muram HT, Boone JM, Brown HL, Jennings SG, Mabie WC, Lombardo GT. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology 2002; 224: 487-492.